Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA’s Health Care Blog, in “FDA’s Combo Products Report Good First Step, Lawyers Say,” by Michael Williamson.
Following is an excerpt:
A Food and Drug Administration report “very correctly identifies” a number of areas where the FDA could improve its combination product review process, an industry attorney recently told me.
Bradley Merrill Thompson, a Washington-based attorney with Epstein Becker & Green, P.C., told me Oct. 16 that while he’s pleased the FDA released the report, “there are other steps the agency could take to strengthen combination product review.” The FDA issued its report Oct. 14 on the combination product review process. The report includes several recommendations from an agency study team.